# The Effect and Safety of Combined Anti-platelet Treatment in Acute Ischemic Stroke Due to Large Artery Atherosclerosis

Study · id `cardio:ct-nct06757764` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06757764](<https://clinicaltrials.gov/study/NCT06757764>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06757764

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 2340 participants.

## Technical summary

Registry record NCT06757764. Randomized; triple masking; primary purpose treatment. Start 2025-07-10 (actual); primary completion 2028-03-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 2340 participants (planned count; ClinicalTrials.gov record NCT06757764, source copy `cardio:ctgov-nct06757764-2026-03-27`, retrieved 2026-10-26)
- Started: 2025-07-10 (actual) (ClinicalTrials.gov record NCT06757764, source copy `cardio:ctgov-nct06757764-2026-03-27`, retrieved 2026-10-26)
- Primary completion: 2028-03-31 (anticipated) (ClinicalTrials.gov record NCT06757764, source copy `cardio:ctgov-nct06757764-2026-03-27`, retrieved 2026-10-26)
- Completion: 2028-03-31 (anticipated) (ClinicalTrials.gov record NCT06757764, source copy `cardio:ctgov-nct06757764-2026-03-27`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT06757764, source copy `cardio:ctgov-nct06757764-2026-03-27`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06757764-2026-03-27`, retrieved 2026-10-26)

## The registry's words

- Brief title: The Effect and Safety of Combined Anti-platelet Treatment in Acute Ischemic Stroke Due to Large Artery Atherosclerosis
- Acronym: CHANGE
- Condition: Cerebral Infarction
- Condition: Stenosis Artery
- Intervention (Drug): Aspirin
- Intervention (Drug): Clopidogrel
- Intervention (Drug): Cilostazol
- Intervention (Drug): Placebo
- Lead sponsor: Asan Medical Center
- Lead sponsor class: OTHER
- Collaborator: Korea Otsuka Pharmaceutical Co., Ltd.
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry intervention name matches this record: Aspirin (`core:aspirin`)
- Registry intervention name matches this record: Clopidogrel (`cardio:clopidogrel`)
- Registry lists this organization as the lead sponsor: Asan Medical Center (`cardio:org-asan-medical-center`)
- Registry lists this organization as a collaborator: Korea Otsuka Pharmaceutical Co., Ltd. (`cardio:org-korea-otsuka-pharmaceutical-co-ltd`)

## Provenance

Content hash: 9b2737ad3868718274049e2b11fc82223fcc1b5b61663fa418d4bf13d858d453
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
